{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:05:32Z","timestamp":1787497532299,"version":"build-2736575974"},"reference-count":52,"publisher":"Scientific Scholar","content-domain":{"domain":["ijdvl.com"],"crossmark-restriction":true},"short-container-title":["IJDVL"],"abstract":"\n Background:<\/jats:title>\n Limited evidence is available about effectiveness and choice of immunomodulating treatment modalities for toxic epidermal necrolysis (TEN).<\/jats:p>\n <\/jats:sec>\n \n Aims:<\/jats:title>\n To compare the effectiveness of interventions to reduce mortality in patients of toxic epidermal necrolysis through network meta-analysis.<\/jats:p>\n <\/jats:sec>\n \n Methods:<\/jats:title>\n Studies were retrieved using PubMed, Google Scholar and Cochrane Database of Systematic Reviews from inception to September 18, 2018. Only English language articles were considered. Observational and randomized controlled studies having \u2265 5 TEN patients in each intervention arm were included. Two investigators independently extracted study characteristics, intervention details and mortality data. Bayesian network meta-analysis was performed using the Markov chain Monte Carlo (MCMC) approach through the random effect model. The ranking analysis was done to provide a hierarchy of interventions. The consistency between direct and indirect evidence was assessed through node spit analysis. The primary outcome was to compare the mortality [Odds ratio OR (95% credibility interval CrI)] among all treatment modalities of TEN.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n Twenty-four studies satisfying the selection criteria were included. The network analysis showed improved survival with cyclosporine as compared to supportive care [OR- 0.19 (95% CrI: 0.05, 0.59)] and intravenous immunoglobulin [OR- 0.21 (95% CrI: 0.05, 0.76)]. The hierarchy of treatments based on \u201csurface under the cumulative ranking curves\u201d (SUCRA) value were cyclosporine (0.93), steroid+intravenous immunoglobulin (0.76), etanercept (0.59), steroids (0.46), intravenous immunoglobulin (0.40), supportive care (0.34) and thalidomide (0.02). No inconsistencies between direct and indirect estimates were observed for any of the treatment pairs.<\/jats:p>\n <\/jats:sec>\n \n Limitations:<\/jats:title>\n Evidence is mainly based on retrospective studies.<\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n The use of cyclosporine can reduce mortality in TEN patients. Other promising immunomodulators could be steroid+intravenous immunoglobulin combination and etanercept.<\/jats:p>\n <\/jats:sec>","DOI":"10.25259\/ijdvl_605_19","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T09:27:45Z","timestamp":1618219665000},"page":"628-644","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Comparison of effectiveness of interventions in reducing mortality in patients of toxic epidermal necrolysis: A network meta-analysis"],"prefix":"10.25259","volume":"87","author":[{"given":"Tejas K.","family":"Patel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parvati B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, GMERS Medical College, Gotri, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sejal","family":"Thakkar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, GMERS Medical College and Hospital, Gotri, Vadodara, Gujarat, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10894","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"10.25259\/IJDVL_605_19\/ref-1","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1001\/archderm.1993.01680220104023","article-title":"Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme","volume":"129","author":"Bastuji-Garin","year":"1993","journal-title":"Arch Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-2","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0378-6323.110749","article-title":"A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population","volume":"79","author":"Patel","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_605_19\/ref-3","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jid.2016.02.196","article-title":"Morbidity and mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis in United States adults","volume":"136","author":"Hsu","year":"2016","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-4","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.alit.2015.09.001","article-title":"Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome","volume":"65","author":"Yamane","year":"2016","journal-title":"Allergol Int"},{"key":"10.25259\/IJDVL_605_19\/ref-5","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098611404094","article-title":"Systematic review of treatments for Stevens-Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality","volume":"2","author":"Roujeau","year":"2011","journal-title":"Ther Adv Drug Saf"},{"key":"10.25259\/IJDVL_605_19\/ref-6","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1060028014560012","article-title":"Corticosteroids in Stevens-Johnson Syndrome\/ toxic epidermal necrolysis: current evidence and implications for future research","volume":"49","author":"Law","year":"2015","journal-title":"Ann Pharmacother"},{"key":"10.25259\/IJDVL_605_19\/ref-7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/j.1365-2133.2012.10965.x","article-title":"The efficacy of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis","volume":"167","author":"Huang","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-8","first-page":"515","article-title":"Intravenous immunoglobulin for the treatment of toxic epidermal necrolysis: A systematic review and meta-analysis","volume":"151","author":"Huang","year":"2016","journal-title":"G Ital Dermatol Venereol"},{"key":"10.25259\/IJDVL_605_19\/ref-9","doi-asserted-by":"publisher","first-page":"e0167120","DOI":"10.1371\/journal.pone.0167120","article-title":"The effect of intravenous immunoglobulin combined with corticosteroid on the progression of Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis","volume":"11","author":"Ye","year":"2016","journal-title":"PLoS One"},{"key":"10.25259\/IJDVL_605_19\/ref-10","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1001\/jamadermatol.2016.5668","article-title":"Systemic immunomodulating therapies for Stevens-Johnson syndrome and toxic epidermal necrolysis: A systematic review and meta-analysis","volume":"153","author":"Zimmermann","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-11","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.dsi.2017.04.004","article-title":"Efficacy of cyclosporine for the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: Systemic review and meta-analysis","volume":"35","author":"Chen","year":"2017","journal-title":"Dermatol Sin"},{"key":"10.25259\/IJDVL_605_19\/ref-12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.2147\/JIR.S160964","article-title":"A meta-analysis of cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis","volume":"11","author":"Ng","year":"2018","journal-title":"J Inflamm Res"},{"key":"10.25259\/IJDVL_605_19\/ref-13","first-page":"133","article-title":"The attractiveness of network meta-analysis: A comprehensive systematic and narrative review","volume":"7","author":"Greco","year":"2015","journal-title":"Heart Lung Vessel"},{"key":"10.25259\/IJDVL_605_19\/ref-14","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.25259\/IJDVL_605_19\/ref-15","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1002\/(SICI)1097-0258(19961230)15:24<2733::AID-SIM562>3.0.CO;2-0","article-title":"Borrowing strength from external trials in a meta-analysis","volume":"15","author":"Higgins","year":"1996","journal-title":"Stat Med"},{"key":"10.25259\/IJDVL_605_19\/ref-16","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1136\/bmj.331.7521.897","article-title":"Simultaneous comparison of multiple treatments: Combining direct and indirect evidence","volume":"331","author":"Caldwell","year":"2005","journal-title":"BMJ"},{"key":"10.25259\/IJDVL_605_19\/ref-17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1136\/bmj.319.7208.508","article-title":"Methods in health service research, An introduction to bayesian methods in health technology assessment","volume":"319","author":"Spiegelhalter","year":"1999","journal-title":"BMJ"},{"key":"10.25259\/IJDVL_605_19\/ref-18","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: An overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.25259\/IJDVL_605_19\/ref-19","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"10.25259\/IJDVL_605_19\/ref-20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1046\/j.1440-0960.2000.00384.x","article-title":"Toxic epidermal necrolysis in Western Australia","volume":"41","author":"Brand","year":"2000","journal-title":"Australas J Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-21","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: Does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.25259\/IJDVL_605_19\/ref-22","doi-asserted-by":"publisher","first-page":"519","DOI":"10.3892\/etm.2015.2549","article-title":"Clinical characteristics and treatment outcome of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"10","author":"Chantaphakul","year":"2015","journal-title":"Exp Ther Med"},{"key":"10.25259\/IJDVL_605_19\/ref-23","first-page":"743","article-title":"High-dose intravenous immunoglobulins in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese patients: A retrospective study of 82 cases","volume":"20","author":"Chen","year":"2010","journal-title":"Eur J Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-24","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.jid.2017.05.022","article-title":"Cyclosporine use in epidermal necrolysis is associated with an important mortality reduction: Evidence from three different approaches","volume":"137","author":"Gonz\u00e1lez-Herrada","year":"2017","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-25","first-page":"119","article-title":"Toxic epidermal necrolysis and Steven Johnson syndrome: 11-years experience and outcome","volume":"11","author":"Gravante","year":"2007","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.25259\/IJDVL_605_19\/ref-26","doi-asserted-by":"crossref","first-page":"978","DOI":"10.4103\/njcp.njcp_122_16","article-title":"Drug-induced Stevens-Johnson syndrome in Indian population: A multicentric retrospective analysis","volume":"20","author":"Hirapara","year":"2017","journal-title":"Niger J Clin Pract"},{"key":"10.25259\/IJDVL_605_19\/ref-27","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/j.1468-3083.1994.tb00362.x","article-title":"Toxic epidermal necrolysis: A study of 22 cases","volume":"3","author":"Ioannides","year":"1994","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.25259\/IJDVL_605_19\/ref-28","doi-asserted-by":"publisher","first-page":"506","DOI":"10.4103\/0378-6323.113080","article-title":"Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: A prospective comparative open-labelled study of 36 cases","volume":"79","author":"Jagadeesan","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_605_19\/ref-29","first-page":"196","article-title":"Elucidation and management of 30 patients of drug induced toxic epidermal necrolysis (DTEN)","volume":"56","author":"Kaur","year":"1990","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_605_19\/ref-30","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/00015550510038232","article-title":"Toxic epidermal necrolysis: Analysis of clinical course and SCORTEN-based comparison of mortality rate and treatment modalities in Korean patients","volume":"85","author":"Kim","year":"2005","journal-title":"Acta Derm Venereol"},{"key":"10.25259\/IJDVL_605_19\/ref-31","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/ijd.12702","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: A 20-year single-center experience","volume":"54","author":"Lalosevic","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-32","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.jaad.2016.07.048","article-title":"Cyclosporine treatment for Stevens-Johnson syndrome\/toxic epidermal necrolysis: Retrospective analysis of a cohort treated in a specialized referral center","volume":"76","author":"Lee","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-33","doi-asserted-by":"publisher","first-page":"312","DOI":"10.4103\/ijdvl.IJDVL_201_16","article-title":"Effectiveness, safety and tolerability of cyclosporine versus supportive treatment in Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis: A record-based study","volume":"83","author":"Mohanty","year":"2017","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_605_19\/ref-34","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/j.0906-6705.2006.00426.x","article-title":"Skin immunoglobulin deposition following intravenous immunoglobulin therapy in toxic epidermal necrolysis","volume":"15","author":"Paquet","year":"2006","journal-title":"Exp Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-35","doi-asserted-by":"publisher","first-page":"1293","DOI":"10.1016\/j.jid.2017.12.034","article-title":"Cyclosporine for epidermal necrolysis: Absence of Beneficial effect in a retrospective cohort of 174 patients-exposed\/unexposed and propensity score-matched analyses","volume":"138","author":"Poizeau","year":"2018","journal-title":"J Invest Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jaad.2007.08.039","article-title":"Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study","volume":"58","author":"Schneck","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-37","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/01.BCR.0000124746.33279.86","article-title":"Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis","volume":"25","author":"Shortt","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"10.25259\/IJDVL_605_19\/ref-38","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/j.burns.2006.08.014","article-title":"Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis","volume":"33","author":"Stella","year":"2007","journal-title":"Burns"},{"key":"10.25259\/IJDVL_605_19\/ref-39","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1172\/JCI93349","article-title":"Randomized, controlled trial of TNF-\u03b1 antagonist in CTL-mediated severe cutaneous adverse reactions","volume":"128","author":"Wang","year":"2018","journal-title":"J Clin Invest"},{"key":"10.25259\/IJDVL_605_19\/ref-40","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/S0140-6736(98)02197-7","article-title":"Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis","volume":"352","author":"Wolkenstein","year":"1998","journal-title":"Lancet"},{"key":"10.25259\/IJDVL_605_19\/ref-41","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1111\/j.1365-4632.2009.04166.x","article-title":"Combination therapy of intravenous immunoglobulin and corticosteroid in the treatment of toxic epidermal necrolysis and Stevens-Johnson syndrome: A retrospective comparative study in China","volume":"48","author":"Yang","year":"2009","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/0885066610390466","article-title":"Serum bicarbonate as a marker to predict mortality in toxic epidermal necrolysis","volume":"26","author":"Yeong","year":"2011","journal-title":"J Intensive Care Med"},{"key":"10.25259\/IJDVL_605_19\/ref-43","doi-asserted-by":"publisher","first-page":"e295","DOI":"10.1097\/BCR.0b013e318254d2ec","article-title":"Toxic epidermal necrolysis: Performance of SCORTEN and the score-based comparison of the efficacy of corticosteroid therapy and intravenous immunoglobulin combined therapy in China","volume":"33","author":"Zhu","year":"2012","journal-title":"J Burn Care Res"},{"key":"10.25259\/IJDVL_605_19\/ref-44","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1111\/j.1365-2133.2010.09863.x","article-title":"Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"163","author":"Valeyrie-Allanore","year":"2010","journal-title":"Br J Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-45","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.jaad.2014.07.016","article-title":"Retrospective review of Stevens-Johnson syndrome\/toxic epidermal necrolysis treatment comparing intravenous immunoglobulin with cyclosporine","volume":"71","author":"Kirchhof","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-46","doi-asserted-by":"publisher","first-page":"e1221","DOI":"10.1097\/GOX.0000000000001221","article-title":"management of toxic epidermal necrolysis with plasmapheresis and cyclosporine A: Our 10 years' experience","volume":"5","author":"Giudice","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"10.25259\/IJDVL_605_19\/ref-47","first-page":"24","article-title":"Cyclosporine for SJS\/TEN: A case series and review of the literature","volume":"87","author":"Reese","year":"2011","journal-title":"Cutis"},{"key":"10.25259\/IJDVL_605_19\/ref-48","doi-asserted-by":"publisher","first-page":"686","DOI":"10.4103\/0378-6323.116738","article-title":"Cyclosporine in Stevens Johnson syndrome and toxic epidermal necrolysis and retrospective comparison with systemic corticosteroid","volume":"79","author":"Singh","year":"2013","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"10.25259\/IJDVL_605_19\/ref-49","first-page":"34","article-title":"Comparison of cyclosporine with systemic corticosteroid in Stevens-Johnson syndrome and toxic epidermal necrolysis-A pilot study","volume":"5","author":"Santosh","year":"2018","journal-title":"Int J Sci Stud"},{"key":"10.25259\/IJDVL_605_19\/ref-50","article-title":"ClinicalTrials.gov","year":"2016","journal-title":"Cyclosporine and Etanercept in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (NATIENS) NCT02987257;"},{"key":"10.25259\/IJDVL_605_19\/ref-51","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/ijd.12423","article-title":"Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis with meta-regression of observational studies","volume":"54","author":"Barron","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.25259\/IJDVL_605_19\/ref-52","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jid.2018.04.027","article-title":"Stevens-Johnson syndrome\/toxic epidermal necrolysis: A multicenter retrospective study of 377 adult patients from the United States","volume":"138","author":"Micheletti","year":"2018","journal-title":"J Invest Dermatol"}],"container-title":["Indian Journal of Dermatology, Venereology and Leprology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ijdvl.com\/comparison-of-effectiveness-of-interventions-in-reducing-mortality-in-patients-of-toxic-epidermal-necrolysis-a-network-meta-analysis\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.ijdvl.com\/comparison-of-effectiveness-of-interventions-in-reducing-mortality-in-patients-of-toxic-epidermal-necrolysis-a-network-meta-analysis\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T20:02:21Z","timestamp":1698868941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ijdvl.com\/comparison-of-effectiveness-of-interventions-in-reducing-mortality-in-patients-of-toxic-epidermal-necrolysis-a-network-meta-analysis\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":52,"alternative-id":["10.25259\/IJDVL_605_19"],"URL":"https:\/\/doi.org\/10.25259\/ijdvl_605_19","relation":{},"ISSN":["0378-6323"],"issn-type":[{"value":"0378-6323","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"article-number":"628"}}